<DOC>
	<DOCNO>NCT02418754</DOCNO>
	<brief_summary>The primary objective study explore effect REGN2176-3 Early Treatment Diabetic Retinopathy Scale ( ETDRS ) best-corrected visual acuity ( BCVA ) patient neovascular age-related macular degeneration ( AMD ) , compare intravitreal aflibercept injection ( IAI ) monotherapy .</brief_summary>
	<brief_title>Study Intravitreal REGN2176-3 Patients With Neovascular ( `` Wet '' ) Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Key 1 . Men woman â‰¥50 year age 2 . Active subfoveal CNV secondary AMD evidence FA study eye , determine reading center , include juxtafoveal lesion affect fovea 3 . BCVA ETDRS letter score 73 24 ( 20/40 20/320 ) study eye screen visit 4 . Provide sign informed consent Key 1 . Any prior treatment antiVEGF treatment study eye 2 . Any prior treatment ( ie , systemic ocular treatment ) PDGF PDGFR inhibitor 3 . Dense fibrotic scar atrophy study eye involve center fovea 4 . Presence retinal pigment epithelial tear rip involve macula study eye 5 . Prior vitrectomy study eye 6 . Any history macular hole stage 2 study eye 7 . Any intraocular periocular surgery within 3 month day 1 study eye , except lid surgery 8 . History corneal transplant study eye 9 . Evidence diabetic retinopathy diabetic macular edema either eye 10 . Positive serum human chorionic gonadotropin/urine pregnancy test screen baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>